Szczepionka przeciw COVID-19 (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Szczepionka przeciw COVID-19" in Polish language version.

refsWebsite

Global rank Polish rank

6doi.org

2^nd place

6^th place

5nih.gov

4^th place

7^th place

2worldcat.org

5^th place

2^nd place

2europa.eu

68^th place

31^st place

1who.int

195^th place

256^th place

1gov.pl

2,590^th place

40^th place

1fda.gov

447^th place

1,118^th place

1pfizer.com

low place

1modernatx.com

low place

1nejm.org

2,374^th place

2,071^st place

1clinicaltrials.gov

5,225^th place

3,508^th place

1jnj.com

low place

1unimelb.edu.au

3,221^st place

low place

clinicaltrials.gov

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19, ClinicalTrials.gov. United States National Library of Medicine, 20 lipca 2020, NCT04470427 (ang.).

doi.org

dx.doi.org

Mark JM.J. Mulligan Mark JM.J. i inni, Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults., „Nature”, 586 (7830), 2020, s. 589–593, DOI: 10.1038/s41586-020-2639-4, PMID: 32785213 .
Alicia T.A.T. Widge Alicia T.A.T. i inni, Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination, „The New England Journal of Medicine”, 384, 2020, s. 80–82, DOI: 10.1056/nejmc2032195, ISSN 0028-4793 .
Lisa A.L.A. Jackson Lisa A.L.A. i inni, An mRNA Vaccine against SARS-CoV-2 – Preliminary Report, „The New England Journal of Medicine”, 383 (20), 2020, s. 1920–1931, DOI: 10.1056/NEJMoa2022483, ISSN 0028-4793, PMID: 32663912, PMCID: PMC7377258 [dostęp 2021-01-10] (ang.).
Pedro MP.M. Folegatti Pedro MP.M. i inni, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial”., „The Lancet”, 396 (10249), 2020, s. 467–478, DOI: 10.1016/S0140-6736(20)31604-4, PMID: 32702298, PMCID: PMC7445431 .
O’ReillyO.’R. P O’ReillyO.’R., „A Phase III study to investigate a vaccine against COVID-19", „ISRCTN”, 2020, DOI: 10.1186/ISRCTN89951424 .
CherylCh. Keech CherylCh. i inni, Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine., „The New England Journal of Medicine”, 383 (24), 2020, s. 2320–2332, DOI: 10.1056/NEJMoa2026920, PMID: 32877576, PMCID: PMC7494251 .

europa.eu

ema.europa.eu

Vaxzevria zawiesina do wstrzykiwań. Szczepionka przeciw COVID-19 (ChAdOx1-S [rekombinowana]). Charakterystyka produktu leczniczego [online], ec.europa.eu, 2021 [dostęp 2020-04-10] .

ec.europa.eu

Decyzja Komisji Europejskiej z 18 czerwca 2020 r. (COMMISSION DECISION of 18.6.2020 approving the agreement with Member States on procuring Covid-19 vaccines on behalf of the Member States and related procedures C(2020) 4192 final) https://ec.europa.eu/info/sites/info/files/decision_approving_the_agreement_with_member_states_on_procuring_covid-19_vaccines_on_behalf_of_the_member_states_and_related_procedures.pdf (europa.eu).

fda.gov

Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) [online], FDA [dostęp 2021-05-25] (ang.).

gov.pl

Narodowy Program Szczepień przeciw COVID-19 [online], gov.pl, grudzień 2020 [dostęp 2021-05-25] .

jnj.com

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older [online] .

modernatx.com

A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older [online] .

nejm.org

Lisa A.L.A. Jackson Lisa A.L.A. i inni, An mRNA Vaccine against SARS-CoV-2 – Preliminary Report, „The New England Journal of Medicine”, 383 (20), 2020, s. 1920–1931, DOI: 10.1056/NEJMoa2022483, ISSN 0028-4793, PMID: 32663912, PMCID: PMC7377258 [dostęp 2021-01-10] (ang.).

nih.gov

ncbi.nlm.nih.gov

Mark JM.J. Mulligan Mark JM.J. i inni, Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults., „Nature”, 586 (7830), 2020, s. 589–593, DOI: 10.1038/s41586-020-2639-4, PMID: 32785213 .
Lisa A.L.A. Jackson Lisa A.L.A. i inni, An mRNA Vaccine against SARS-CoV-2 – Preliminary Report, „The New England Journal of Medicine”, 383 (20), 2020, s. 1920–1931, DOI: 10.1056/NEJMoa2022483, ISSN 0028-4793, PMID: 32663912, PMCID: PMC7377258 [dostęp 2021-01-10] (ang.).
Pedro MP.M. Folegatti Pedro MP.M. i inni, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial”., „The Lancet”, 396 (10249), 2020, s. 467–478, DOI: 10.1016/S0140-6736(20)31604-4, PMID: 32702298, PMCID: PMC7445431 .
CherylCh. Keech CherylCh. i inni, Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine., „The New England Journal of Medicine”, 383 (24), 2020, s. 2320–2332, DOI: 10.1056/NEJMoa2026920, PMID: 32877576, PMCID: PMC7494251 .

nih.gov

NIH clinical trial of investigational vaccine for COVID-19 begins [online], National Institutes of Health (NIH), 16 marca 2020 [dostęp 2021-01-10] (ang.).

pfizer.com

cdn.pfizer.com

A phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of Sars-Cov-2 RNA vaccine candidates against COVID-19 in healthy individuals. PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001 [online] .

unimelb.edu.au

medicine.unimelb.edu.au

COVID-19 Weekly Vaccine Updates No. 51. University of Melbourne, 2022-06-09. [dostęp 2022-06-16]. (ang.).

who.int

DRAFT landscape of COVID-19 candidate vaccines [online], WHO, 10 grudnia 2020 [dostęp 2021-05-25] (ang.).

worldcat.org

Alicia T.A.T. Widge Alicia T.A.T. i inni, Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination, „The New England Journal of Medicine”, 384, 2020, s. 80–82, DOI: 10.1056/nejmc2032195, ISSN 0028-4793 .
Lisa A.L.A. Jackson Lisa A.L.A. i inni, An mRNA Vaccine against SARS-CoV-2 – Preliminary Report, „The New England Journal of Medicine”, 383 (20), 2020, s. 1920–1931, DOI: 10.1056/NEJMoa2022483, ISSN 0028-4793, PMID: 32663912, PMCID: PMC7377258 [dostęp 2021-01-10] (ang.).